Ignite Creation Date:
2025-12-25 @ 3:02 AM
Ignite Modification Date:
2026-01-01 @ 6:22 AM
Study NCT ID:
NCT06824233
Status:
NOT_YET_RECRUITING
Last Update Posted:
2025-02-13
First Post:
2025-02-07
Is NOT Gene Therapy:
True
Has Adverse Events:
False
Brief Title:
Diabetic Cardiovascular Complications: Multi-Omics Analysis
Sponsor:
Second Xiangya Hospital of Central South University
Organization:
Study Overview
Official Title:
Deciphering the Molecular Landscape of Diabetic Cardiovascular Complications Based on Multi-Omics Analysis
Status:
NOT_YET_RECRUITING
Status Verified Date:
2025-02
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
D-CCMOA
Brief Summary:
The goal of this observational study is to learn about the molecular mechanisms underlying cardiovascular complications in individuals with type 2 diabetes (T2DM) and how they differ from healthy individuals. The study will also identify biomarkers and potential therapeutic targets for better managing diabetes-related heart disease.
The main questions it aims to answer are:
1. What molecular changes are associated with cardiovascular complications in T2DM patients compared to healthy individuals?
2. How do genetic, gene expression, and protein profiles differ between T2DM patients with and without cardiovascular complications? Researchers will compare the molecular profiles of three groups: healthy controls, individuals with T2DM but no cardiovascular complications, and those with T2DM and cardiovascular complications.
Participants will:
1. Provide blood samples for genomics, transcriptomics, and proteomics analysis
2. Undergo standard clinical tests such as blood pressure, echocardiogram, and ankle-brachial index measurements
3. Be followed for 12 to 24 months to track the development of cardiovascular events Participate in follow-up phone interviews to record major cardiovascular events like heart attacks or strokes
The main questions it aims to answer are:
1. What molecular changes are associated with cardiovascular complications in T2DM patients compared to healthy individuals?
2. How do genetic, gene expression, and protein profiles differ between T2DM patients with and without cardiovascular complications? Researchers will compare the molecular profiles of three groups: healthy controls, individuals with T2DM but no cardiovascular complications, and those with T2DM and cardiovascular complications.
Participants will:
1. Provide blood samples for genomics, transcriptomics, and proteomics analysis
2. Undergo standard clinical tests such as blood pressure, echocardiogram, and ankle-brachial index measurements
3. Be followed for 12 to 24 months to track the development of cardiovascular events Participate in follow-up phone interviews to record major cardiovascular events like heart attacks or strokes
Detailed Description:
None
Study Oversight
Has Oversight DMC:
False
Is a FDA Regulated Drug?:
False
Is a FDA Regulated Device?:
False
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
False
Is an FDA AA801 Violation?: